DeepMed Research

Mabwell (Shanghai) Bioscience Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Subsidiary

Established: 2017-05-12

Employees: 1.4K

Market Cap: -

Website: https://www.mabwell.com

Clinical Trials

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Phase 1

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: 9MW0813
Drug: Aflibercept

First Posted Date: 2022-04-12

Last Posted Date: 2022-04-12

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 24

Registration Number: NCT05324592

Locations: 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Phase 2

Conditions: Wet Age-related Macular Degeneration

Interventions: Drug: Lucentis
Drug: MW02

First Posted Date: 2022-03-28

Last Posted Date: 2022-03-28

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 433

Registration Number: NCT05297292

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Si Chuan, China

A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumors

Interventions: Drug: 9MW2821

First Posted Date: 2022-02-01

Last Posted Date: 2022-06-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 208

Registration Number: NCT05216965

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of MW031 in PMO Subjects

Phase 3

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Placebo
Drug: MW031

First Posted Date: 2022-01-31

Last Posted Date: 2023-10-11

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 448

Registration Number: NCT05215977

Locations: 🇨🇳
Peking Union Hospital, Beijing, Beijing, China

A Clinical Study in Healthy Subjects to Evaluate 9MW1911 Injection

Phase 1

Completed

Conditions: COPD
Asthma
Atopic Dermatitis

Interventions: Drug: 9MW1911 Injection Placebo
Drug: 9MW1911 Injection

First Posted Date: 2021-12-27

Last Posted Date: 2023-12-11

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 28

Registration Number: NCT05170243

Locations: 🇨🇳
Shanghai Public Health Center, Shanghai, Shanghai, China

A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm

Phase 1

Recruiting

Conditions: Advanced Malignant Neoplasm

Interventions: Drug: Intravenous Infusion

First Posted Date: 2021-09-17

Last Posted Date: 2022-05-09

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 272

Registration Number: NCT05048160

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Phase 3

Completed

Conditions: Bone Metastases

Interventions: Drug: MW032
Drug: Xgeva

First Posted Date: 2021-03-23

Last Posted Date: 2023-02-24

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 708

Registration Number: NCT04812509

Locations: 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW031 and Prolia® in Healthy Adults

Phase 1

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: Prolia®
Drug: MW031

First Posted Date: 2021-03-15

Last Posted Date: 2021-03-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04798313

Locations: 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults

Phase 1

Completed

Conditions: Bone Tumor

Interventions: Drug: Xgeva®
Drug: MW032

First Posted Date: 2021-03-15

Last Posted Date: 2021-03-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04798326

Locations: 🇨🇳
PKUCare Luzhong Hospital, Zibo, Shandong, China

A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection

Phase 1

Completed

Conditions: Staphylococcus Aureus Infection

Interventions: Combination Product: 9MW1411 injection placebo
Combination Product: 9MW1411 injection

First Posted Date: 2021-03-05

Last Posted Date: 2022-06-15

Lead Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.

Target Recruit Count: 42

Registration Number: NCT04784312

Locations: 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy